Aralez Pharmaceuticals agrees to sell main operating businesses
Aralez has signed an agreement to sell its VIMOVO royalties and Canadian operations to Nuvo Pharmaceuticals for $110m. In another deal, the company agreed to offload its TOPROL-XL
Aralez has signed an agreement to sell its VIMOVO royalties and Canadian operations to Nuvo Pharmaceuticals for $110m. In another deal, the company agreed to offload its TOPROL-XL
The financing was led by Novo Holdings and joined by new investors Cowen Healthcare Investments, Pfizer Ventures and funds managed by Tekla Capital Management. Existing investors Versant Ventures,
Continuing its focus on enhancing shareholder value, the Board believes a separation of the Rx business will better enable this unique asset to capitalize on its platform of
The product is a novel therapeutic antibody, Clevegen, being developed by clinical stage biotechnology company, Faron Pharmaceuticals. The manufacture of this product took place at Abzena’s site in
Spark Therapeutics reported that although most of the patients could have their bleeding reduced by its gene therapy, one participant though did not quickly respond to oral steroids. The
The fast track designation gives BioCryst Pharmaceuticals the scope for frequent interactions with the FDA during development of the drug. It also gives the opportunity for priority review
Kapspargo Sprinkle, a U.S. Food and Drug Administration (FDA) approved, novel, patented formulation of metoprolol succinate, is the first and only extended-release sprinkle formulation of this beta1-selective adrenoreceptor
With this decision, eligible adults in the UK with hATTR amyloidosis can gain access to patisiran before the drug is granted marketing authorization by the European Commission (EC).
The phase 2 trial evaluated ridinilazole against Standard of Care vancomycin across 100 patients. By preserving the gut microbiome, the Summit drug was demonstrated to have brought down
The company’s announcement also included the issuance of $22m in shares upon conversion of debt into equity Participants included ARCH Venture Partners, the Wellcome Trust, Steven Paul M.D.,